Elsevier

Thrombosis Research

Volume 130, Issue 6, December 2012, Pages 853-858
Thrombosis Research

Regular article
Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: A meta-analysis of 5 randomized trials in non-cancer and cancer patients

https://doi.org/10.1016/j.thromres.2012.08.290Get rights and content

Abstract

Purpose

Due to its specific pharmacokinetic profile, tinzaparin, a low-molecular-weight heparin (LMWH), appears not to be associated with anti-factor Xa accumulation. Our meta-analysis aimed at determining whether long-term curative doses of tinzaparin is a valuable alternative to vitamin K antagonists (VKA) for the treatment of symptomatic venous thromboembolism (VTE), especially in patients with cancer who are at higher risk of recurrence and bleeding.

Materials and Methods

A systematic literature search identified randomized studies on long-term tinzaparin compared to VKA in patients with VTE. Outcome measures were VTE recurrence, major bleeding, deaths and net clinical benefit combining the three endpoints during the treatment period and at one year. Pooled relative risk was estimated using the logarithm of the relative risk (RR) method based on a fixed-effect model in the overall population and cancer population.

Results

Five randomized controlled studies were eligible. No difference between groups in VTE recurrence was found in the overall population (RR = 0.85 [0.55; 1.31]). In cancer patients, a non-significant 38% VTE risk reduction in favor of tinzaparin was observed on treatment (RR = 0.62 [0.30; 1.31]). The difference was significant at the end of follow-up at one year (RR = 0.40 [0.19; 0.82], p < 0.01). The incidence of major bleeding in the tinzaparin group was not significantly different from the VKA group in the overall population and cancer patients.

Conclusions

Tinzaparin appears as a valuable option for long-term treatment of patients in whom VKA are contraindicated or difficult to monitor. Tinzaparin may have a more favorable benefit-risk ratio than VKA in patients with cancer and VTE.

Introduction

Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep-vein thrombosis (DVT) is a major cause of morbidity and mortality, affecting over 2 million people in the United States [1], [2], [3]. Patients with cancer face a significant increase in the incidence of VTE compared to non-cancer patients, of at least 7-fold in certain malignancies [4].

Patients with proximal DVT or PE require anticoagulant treatment for at least 3 months to prevent symptomatic extension and/or recurrent VTE [5], [6]. Standard therapy includes initial unfractionated heparin (UHF), low-molecular-weight heparin (LMWH) or pentasaccharides followed by vitamin K antagonists (VKA) which have been considered for decades as the reference long-term anticoagulant therapy in patients with symptomatic VTE as oral administration is effective and more convenient for long-term treatment [7], [8]. VKA reduce the risk of VTE recurrence as long as they are used [9]. However, the high variability in the response to VKA requires regular INR monitoring and dose adaptation. Although VKA achieves a low rate of recurrent VTE in the general population of patients with VTE (10), its use is associated with a high recurrence rate in patients with cancer (11).

LMWH has been considered as an effective and safe alternative for the long-term anticoagulant treatment in patients with side effects or other complications on VKA [10] or in patients in whom the use of VKA would be contraindicated or problematic [11]. The issue of the benefit-risk ratio of long-term curative doses of LMWH and their potential advantage compared to VKA is not fully addressed [12]. Based on a meta-analysis of randomized trials, early comparisons of LMWH to VKA for the long-term treatment of symptomatic VTE showed a statistically non-significant reduction in the risk of VTE at 3 months (OR 0.66 [95%CI 0.41; 1.07]) and in the risk of bleeding (OR 0.45 [95%CI 0.18; 1.11]) in favor of LMWH treatment [11]. Previous reviews or meta-analyses in adult patients with cancer have shown that the long-term use of LMWH after the acute first week of treatment is superior to VKA for secondary prevention of venous thromboembolism [13], [14], [15]. Overall, meta-analyses on LMWH show a reduction of VTE recurrence and bleeding risk compared to VKA but statistical significance is not reached. This may be due to: i) old studies with sub-optimal methodology, ii) the mix in clinical studies of cancer and non-cancer patients who are at different levels of risk, iii) the inclusion of different LMWHs in the same analyses.

Only one of the available LMWH, dalteparin, has received formal approval for the long term treatment of patients with cancer at curative doses, based on the CLOT study [16]. However, enoxaparin and tinzaparin (Innohep®, LEO Pharma) curative doses are also recommended by academic and regulatory guidelines for the long-term treatment of symptomatic VTE in patients with cancer [7], [8], [17], [18], [19]. Tinzaparin has the highest molecular weight compared to other LMWH. It is not exclusively eliminated by the kidney as the reticulo-endothelial system and the liver contribute to tinzaparin metabolism (21). Therefor unlike other LMWHs such as enoxaparin, tinzaparin does not seem to cause an accumulation of anti-factor Xa activity in patients with renal insufficiency [20], [21] which is of particular interest in patients with cancer with a high prevalence of renal impairment (24) in whom tinzaparin could be associated with a lower risk of bleeding.

The purpose of this meta-analysis is to assess the benefit-risk ratio of the LMWH, tinzaparin, when used at curative doses for the long-term treatment of patients with symptomatic VTE, in comparison to VKA.

Section snippets

Literature search and study identification

Our aim was to identify all the relevant published and unpublished randomized controlled trials (RCTs) comparing long-term tinzaparin (3–6 months), at the curative dosage of 175 IU/kg once daily for the treatment of VTE to a vitamin K antagonist adjusted to maintain an INR of 2 to 3. An exhaustive literature search, both manual and computer assisted, was performed without any restriction on language or dates. The computer-assisted search was carried out on electronic databases (MEDLINE, the

Search strategy and studies description

Out of 266 citations found after electronic search, 256 were discarded for various reasons (Fig. 1). One was added after a manual search. A total of 11 were carefully reviewed, 5 studies were found eligible to the meta-analysis (Fig. 1) and are described in Table 1 (6, 30–33). There was no discordance in the selection of the study. A total of 1668 patients with symptomatic VTE of whom 406 had cancer were enrolled in the studies, all treated with curative doses of tinzaparin (n = 835) or VKA (n = 

Discussion

The 5 eligible randomized clinical trials included in this meta-analysis compared long-term (3 to 6 months) curative treatment with tinzaparin to VKA (warfarin or acenocoumarol) for the prevention of thromboembolic recurrence in 1668 patients with symptomatic VTE, of whom 406 (24%) had cancer. When combining these trials, long-term treatment with tinzaparin was associated with a 15% non-significant relative risk reduction of VTE-recurrence compared to VKA after 3–6 month treatment period. This

Conflict of interest statement

No conflict for this manuscript.

References (36)

  • P. Lopez-Beret et al.

    Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis

    J Vasc Surg

    (2001)
  • M.D. Silverstein et al.

    Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

    Arch Intern Med [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]

    (1998)
  • R.H. White

    The epidemiology of venous thromboembolism

    Circulation

    (2003)
  • M. Houman Fekrazad et al.

    Treatment of venous thromboembolism: guidelines translated for the clinician

    J Thromb Haemost

    (2009)
  • S. Noble et al.

    Epidemiology and pathophysiology of cancer-associated thrombosis

    Br J Cancer

    (2010)
  • G. Agnelli et al.

    Treatment of DVT: how long is enough and how do you predict recurrence

    J Thromb Haemost

    (2008)
  • R.D. Hull et al.

    Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome

    Am J Med

    (2009)
  • C. Kearon et al.

    Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

    Chest

    (2012)
  • Cited by (24)

    • Complications of disease and therapy

      2023, DiSaia and Creasman Clinical Gynecologic Oncology
    • American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer

      2021, Blood Advances
      Citation Excerpt :

      Different DOACs have different drug-drug interactions. We identified 11 systematic reviews addressing this question.304-313 From these reviews, we identified 8 eligible RCTs that fulfilled our inclusion criteria and measured outcomes relevant to this question.314-319

    • Editor's Choice – A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer

      2019, European Journal of Vascular and Endovascular Surgery
      Citation Excerpt :

      Modern therapeutic strategies with a LMWH or DOAC are more effective in preventing VTE recurrence compared with standard therapy with VKA, but they had no effect on the overall mortality in the present study. Treatment with LMWH has a lower risk of recurrent VTE than VKAs, and several studies and meta-analyses agree with these results.37–41 Similar effects for the recurrence VTE have been described for patients with and without cancer.41

    • Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences

      2018, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      According to the different international clinical guidelines, low-molecular-weight heparins (LMWH) are currently the preferred option for the treatment of CAT (Table 1) (Farge et al., 2016; Kearon et al., 2012; Khorana, 2007; Lyman et al., 2015) as they were shown superior to vitamin K antagonists (VKA) in preventing VTE recurrence (Posch et al., 2015). Despite the evidence (Akl et al., 2008; Laporte et al., 2012), there are substantial reports from observational studies of insufficient compliance with established treatment guidelines (Delate et al., 2012; Kahn et al., 2012; Sevestre et al., 2014; Spirk et al., 2011; Trujillo-Santos et al., 2010; Khorana et al., 2016) even though recent studies have shown that long-term LMWH were well accepted by patients with CAT (Cajfinger et al., 2016) and that physicians tended to underestimate patients’ ability to accept long-term LMWH (Cimminiello and Anderson, 2012). There is no robust evidence of the efficacy of direct oral anticoagulants (DOAC) for the long-term treatment of CAT.

    • Complications of disease and therapy

      2018, Clinical Gynecologic Oncology
    View all citing articles on Scopus

    Disclosure of funding received for this work: None.

    View full text